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Trifluorolnethyl Ketones Show Culture Age-dependent Inhibitory 
Effects on Low K+_induced Apoptosis in Cerebellar Granule 
Neurons 
KATSUYOSHI SUNAGA, TORU TANAKA, SATORU TANl and MASAMI KAWASE 
Faculty of Pharmaceutical Sciences, Josai University, Sakado, Saitama 350-0295, Japan 
Abstract. We previously reported that two tnfluoromethyl 
ketones, 3,3,3-tnfluor0-1-phenyl-1,2-propanedione (TF1) and 
1, 1, 1-tnfluor0-3-phenyl-2-pro anone (TF2), have neuroprote-
ctive effects against low K -induced apoptosis in cerebellar 
g7lanule neurons (CGNs) exposed at 12-13 days in vitro (DIV). 
On the other hand, these compounds showed weak neuro-
protective potency against 7 DIV CGNs. It is reported that 
actinomycin D (Act-D), cycloheximide (CHX), and caspase i 
inhibitors prevent the apoptosis of CGNS induced by K 
deprivation. However, these experiments are generally performed 
using 7 DIV CGNs. We investigated and compared the anti-
apoptotic efficacy of these drugs and newly-discovered TFI and 
TF+2 to protect DIV 7 and 12-13 CGNS from death+ induced by 
K deprivation. Apoptosis of CGNS induced by K withdrawal 
at 13 DIV was potently inhibited by Act-D and CHX similar to 
those at 7 DIV Cas ase-3 inhibitors moderately suppressed cell ･ ~ death during low K -induced apoptosis both exposed 7 and 13 
DIV Serine protease inhibitor N-tosyl-L+~Phenylalanyl chloro-
methylketone (TPCK) had no effect on K -deprivation-induced 
apoptosis of CGNS at both 7 and 12 DIV This study showed 
that there are dlfferent pathways of apoptosis in CGNS 
depending on the culture age. 
Potassium (K+) deprivation-induced apoptosis of cerebellar 
granule neurons (CGNs) r~epresents one of the best in vitro 
models of neuronal apoptosis (1, 2). This culture system is 
also a good method for screening many compounds in order 
to find effective apoptosis inhibitors. The cultures of CGNs 
are formed by a homogenous population of granule neurons 
which can survive up to 15 days when they are maintai+ned in 
fetal bovine serum supplemented with 25 mM k (3). 
Apoptosis of C+GNs can be induced by lowering the 
extracellular K concentration from 25 to 5 mM, as 
Correspondence to: Dr. Katsuyoshi Sunaga, Faculty of Pharma-
ceutical Sciences, Josai University, Sakado, Saitama 350-0295, 
Japan. Tel: +81-492-86-2233, Fax: +81-492-71-7984, e-mail: 
ksunaga@ josai.ac. jp 
Key Words: Trifluoromethyl ketone, neuroprotection, apoptosis, 
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evidenced by morph l gical and biochemical meth0+ds (1, 2, 
4). Death of CGNs induced by switching to 5 mM K can be 
prevented by several compounds, such as actinornycin D (Act-
D) (4), cycloheximide (CHX) (4), fullaren derivatives (5), 
forskolin (6) and ca~pase-3 inhibitors (Z-DEVD and Z-VAD-
FMK) (7), but not by the chymotrypsin inhibitor (TPCK), 
trypsin inh bitor (TLCK) and caspase-1 inhibitors (Ac-
YVAD-CHO) (4). Thes experiments are generally 
performed using CGNs on days in vitro (DIV) 7-8. During our 
screening program of apoptosis inhibitors, we found that 
PhCOCOCF3 (TF1) and PhCH2COCF3 (T+F2) prevent the 
apoptosis of DIV 12-13 CGNs induced by K deprivation, but 
not the apoptosis of DIV 7 CGNs (Fi:,ure 1). Compounds 
TFI a  TF2 showed sirnilar neuroprotective potency to Act-
D and CHX (8). 
Therefore, we studied the effects of several drugs such as 
Act-D, CHX, caspase inhibitors, serine protease inhibitors 
and newly-disc+0vered TFI and TF2 on apoptosis of CGNs 
induced by K deprivation at both DIV 7 and 12-13. The 
purpose of thi  study was to compare the anti-apoptotic 
efficacy of the e drugs t+0 protect DIV 7 and 12-13 CGNs , 
from death induced by K deprivation. 
Materials and Methods 
Cell culture. Cul es enriched in granule neurons were obtained from 8-
day-old Wistar rats as described previously (9). The cells were plated in 
basal medium Eagle (BME) supplemented with 10% fetal bovine serum, 
2 mM L-glutamine, 25 mM KCI and 50 ug/mL gentamicin on 48-well 
plate c ated with poly-L-lysine. The cells were plated at a density of 2.5 5 2 x 10 /cm . Cytosine-B-D-arabinofuranoside (AraC, 10 uM) was added 
to he culture medium 18-22 hours after plating to prevent proliferation 
of nonneurQnal cells. Cultures generated by this method have been 
characterized and shown to contain >95% granule neurons. 
Treatment of cultures and assessment of neuronal survival. After 7 or 12-13 
days in vitro (DIV) in 25 mM KCI medium, the culture medium was 
replaced with serum-free BME medium containing 5 mM KCI and 
supplemented with L-glutamine, gentamicin and AraC at the 
concentrations indicated above (LK). The test compounds were 
dissolved and diluted in ethanol and 200-fold concentrated compounds 
were added directly to the low K+/serum-free mediun~. Control cultures 
were maintained in serum-free BME medium supplemented with 25 mM 
KCI (HK). 
After 20-24 hours maintained in LK or HK, neuronal survival was 
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viability of CGNs decreased by > 50% when measured after 
24 hours, as similarly described by others (1, 4). 
Fragmentation of genomic DNA is a hallmark of apoptosis 
and such fragmentation is induced in DIV 7 CGNS by ?
switching to a low K medium (1~). This is also illustratedT/1,n 
Figure 3, showing the same DNA fragmentation in *. -
deprived DIV 12-13 CGNs. 
The ability of seyeral apoptosis inhibitors to limit CGN 
death induced by K deprivation as a function of culture age 
was studied. First, newly-discovered apoptosis inhibitors T~'-<} 
and TF2 blocked the death of CGNs induced by *~ 
withdrawal at DIV 12-13, but not at DIV 7. The dose-
response relationships of neuroprotective effects by TFI and 
TF2 are shown in Figure 4. When apoptosis was induced at 13 
DIV, both TFI and TF2 potently protected neuronal 
apoptosis in dose-dependent manner, in which maximum 
protection was approximately 66% at 10 uM and 56% at 100 
Lt, M, respectively. In the case of TF1, excess of 30 ~t.M reduced 
neuroprotective effects, showing a bell-shape curve. On the 
other hand, when apoptosis was induced at 7 DIV, 
neuroprotection by TFI and TF2 was very weak, 
approximately only 30% protection at 100 uM concentration. 
These protective effects of TF compounds were not affected 
by supplementation of glucose at 10 DIV, which prolonged 
cell Survival more than a further seven da~s (data not shown). 
Second, apoptosis of CGN induced by K withdrawal at both 
DIV 7 and 1213 was mhibrted by Act D (a RNA 
transcription inhibitor) and CHX (a protein synthesis 
inhibitor) (Figure 5). Third, Z-VAD-FMK, a non-selective 
caspase inhibitor and Z-DEVD-FMK, a selective inhibitor of 
caspase-3 (CP+P32/Apopain) moderately suppressed cel] death 
from low IC -induce  apoptosis in DIV 7 and 12 CGNs 
(Figu e 6). In contrast, AC-YVAD-CHO, a selective inhibitor 
of caspase-1, did not block apoptosis induced by low K+ in 
DIV 7 and 12-13 CGNs. Fourth, the chymotrypsin inhibitor, 
N-tosyl-L-ph+enyla anyl chloromethylketone (TPCK), had no 
ffect on K deprivation-induced apoptosis of DIV 7 (8) and 
12-13 CGNs at concentrations tolerated by the CGNs (data 
not shown). 
Discussion 
Apoptosis s prominent n normal developing CNS, in certain 
genetic diseases and after some forms of CNS injury (11, 12). 
Neurodeg nerative diseases also involve apoptotic cell death 
(13). Recent studies have suggested that apoptosis inhibitors 
can prevent a neurodegenerative disease (14, 15). Conse-
quently, apoptosis inhibitors can be considered as potential 
neurorescuing agents. As the cultures of CGNS are formed by 
a homogeneous p pulation of granule neurons and large 
amounts of CGNs are easily obtained, this culture system can 
be suitable for screening effective apoptosis inhibitors. 
During our progr m for screening apoptosis inhibitors, we 
foun that some TF compounds blocked the apoptosis of 
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DIV 12-1<3 CGNs, b~t not the apoptosis of DIV 7 CGNs. This 
indic',rted that K -deprivecl CGNS Showed increasing 
sensitivity to TF compounds between DIV 7 and 12-13. 
We undertook some experiments to elucidate the molecular 
mechanisms underlying the differences between apoptosis 
incluced at 7 and 12-13 DIV. We showed that Act-D, CHX 
',mcl caspase~3 inhibitors rescuecl both 7 and 12-13 DIV from 
death by K deprivation; however, caspase-1 inhibitor and 
serine protease inhibitors dicl not prevent apoptosis of either 
7 or :12-13 DIV. These results indicated that apoptosis 
incluced at both 7 and 12-13 DIV similarly recluire new 
protein synthesis and activ'ation of caspase-3. However, the 
apoptosis-inhibitory activity of TFI and TF2 was unrelated to 
the inhibition of caspase-3 (8). 
It is speculated that some p',rthways to apoptosis of matured 
CGNS (7 DIV) would disappear anci/or a new pathway 
'appe'ars between 7 and 12-13 DIV. In this regard, con-
siderable results have been reported that responsiveness of 
CGNs to neurotrophins change (16-1.8) and p75NTR falls 
dr'astically dur,ing cerebellar development (16). Furthermore, 
it is reported that up-regulation of, cyclin Dl mRNA is 
accompanied with apoptosis of immature but not mature 
CGNS (19). These results suggest that there are different 
pathways of neuronal apoptosis depending on differentiation 
or aging state of the cultured neurons. 
Ho, wever, the possibility of changes in the permeability of 
the cell membrane for TF compounds by the culture ages (7 
ancl 1~2-13 DIV) can not be ruled out. In this regard, a high 
close (1+OO ~LM) of TF compounds slightly rescued CGNS from 
low K -induced apoptosis on 7 DIV culture (Figure 2). 
Moreover, the neuroprotective property of other neuro-
protective 'agents, such as Act-D, CHX, Z-DEVD-FMK and 
Z-VAD-FMK, which are thought to act at intracellular 
compartment, rem'ained unchanged during aging. It is 
reportecl that TPCK blocked caspase-3, -8 and -9 activation 
and apoptosis during hypoxiareoxygenation (20); ho¥vever i,n 
our experiments, TPCK had no protective effect on low K -
induced apoptosis at both 7 and 12-13 DIV. These results 
suggested that membi-ane perme'ability for various agents 
could be related to expression of th~se biochemical effects. 
Although various factors in low K -induced apoptosis of 
CGNS are considered, this culture system would be useful for 
research of various mechanisms of apoptosis and screening of 
new 'apoptosis_-preventing agents by evaluation at some 
deveiopmental stage (7 and 12-13 DIV) of the culture. 
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